Openshaw Mark R, Fotopoulou Christina, Blagden Sarah, Gabra Hani
Department of Medical Oncology, Hammersmith Hospital, Imperial College NHS, London, UK.
Womens Health (Lond). 2015 Jun;11(3):355-67. doi: 10.2217/whe.15.6.
Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication. Second, acquisition of chemotherapy resistance results in untreatable progressive disease. Advances in treatment of advanced ovarian cancer involve a spectrum of interventions including improvements in frontline debulking surgery and combination chemotherapy. Anti-angiogenic factors have been shown to have activity in frontline and recurrent disease while novel chemotherapeutic agents and targeted treatments are in development particularly for disease that is resistant to platinum-based chemotherapy. These developments aim to improve the progression-free and overall survival of women with advanced ovarian cancer.
全球范围内，每年有超过20万名女性受卵巢癌影响。总体生存率较低主要有两个原因。第一，大多数患者就诊时已处于晚期，这给彻底根除疾病带来了巨大困难。第二，获得化疗耐药性会导致疾病进展至无法治疗。晚期卵巢癌治疗的进展涉及一系列干预措施，包括一线减瘤手术和联合化疗的改进。抗血管生成因子已被证明在一线治疗和复发性疾病中具有活性，同时新型化疗药物和靶向治疗正在研发中，特别是针对对铂类化疗耐药的疾病。这些进展旨在提高晚期卵巢癌女性的无进展生存期和总生存期。
